aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.794
+0.003 (0.34%)
At close: Apr 28, 2026, 4:00 PM EDT
0.790
-0.004 (-0.45%)
After-hours: Apr 28, 2026, 5:27 PM EDT
aTyr Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for aTyr Pharma stock have an average target of 3.67, with a low estimate of 1.00 and a high estimate of 17. The average target predicts an increase of 362.45% from the current stock price of 0.79.
Analyst Consensus: Hold
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for aTyr Pharma stock from 9 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 8 | 8 | 8 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $1.5 → $1 | Hold | Maintains | $1.5 → $1 | +26.01% | Nov 7, 2025 |
| Freedom Broker | Freedom Broker | Strong Buy → Hold Downgrades $9.5 → $1 | Strong Buy → Hold | Downgrades | $9.5 → $1 | +26.01% | Sep 19, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $25 → $1 | Buy → Hold | Downgrades | $25 → $1 | +26.01% | Sep 16, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $16 → $1.5 | Buy → Hold | Downgrades | $16 → $1.5 | +89.01% | Sep 16, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $1 | Buy → Hold | Downgrades | $1 | +26.01% | Sep 15, 2025 |
Financial Forecast
Revenue This Year
n/a
from 190.00K
Revenue Next Year
10.24M
EPS This Year
-0.61
from -0.80
EPS Next Year
-0.47
from -0.61
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 73.8M | ||||||
| Avg | n/a | 10.2M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.40 | -0.12 | ||||||
| Avg | -0.61 | -0.47 | ||||||
| Low | -0.74 | -0.65 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.